Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

NCT07702032 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

960

Enrollment

INDUSTRY

Sponsor class

Conditions

Left-sided Colorectal Cancer

Interventions

DRUG: Petosemtamab
DRUG: Cetuximab
DRUG: FOLFIRI
DRUG: mFOLFOX6

Sponsor

Genmab